Notably, mice treated with anti–TIM-3 Ab without allogeneic Tc transfer were not protected from FLT3-ITD MLL-PTD–driven AML (Figure 1J), indicating that anti–TIM-3 Ab requires allo-HCT to exert its effects. The gene discussed is FLT3; the disease is acute myeloid leukemia.